Demand for CSL’s Plasma Products Persists as Supply Improves
CSL’s balance sheet is in sound condition. Financial risk is low given low revenue cyclicality and product demand is being largely driven by chronic indications. We forecast CSL’s net debt to EBITDA ...
INFORMATION NIGERIA3h
Siblings Caught Trying To Sell Stolen N15m Property For N70,000 In Ekiti
The Ekiti State Amotekun Corps has arrested two siblings for allegedly stealing and attempting to sell home property valued ...
Livewire Markets5h
CSL falls short, despite $8.48 billion revenue
CSL Seqirus, the vaccination segment, was affected by low influenza vaccination rates in the US, dragging down overall ...
CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business — Update
Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.
CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update
Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.